Structure/function relationships of calcitonin analogues as agonists, antagonists, or inverse agonists in a constitutively activated receptor cell system

Molecular Pharmacology

Volumn 51, Issue 4, 1997, Pages 658-665

  Pozvek, Gordana ^a   Hilton, Joanne M ^a   Quiza, Maribel ^a   Houssami, Souheir ^a   Sexton, Patrick M ^a  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AC 512; CALCITONIN DERIVATIVE; CALCITONIN RECEPTOR; SALCATONIN; SDZ 212 769; SDZ 216 710; SDZ 218 686; SDZ 219 379; SDZ 220 235; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

EID: 0031002114     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.51.4.658     Document Type: Article

References (40)

1. Zaidi, M., B. S. Moonga, P. J. R. Bevis, A. S. M. Towhidul Alam, S. Legon, S. Wimalawansa, I. Maclntyre, and L. H. Breimer. Expression and function of calcitonin gene products. Vitamins Hormones 46:87-164 (1991).
2. Sexton, P. M. Central nervous system binding sites for calcitonin and calcitonin gene-related peptide. Mol. Neurobiol. 5:251-273 (1991).
3. Wisneski, L. A. Review of calcitonin: future perspectives and new opportunities in therapy. Bone Mineral. 16:213-216 (1992).
4. Chesnut, C. H., III. Review of calcitonin-present: current status of calcitonin as a therapeutic agent. Bone Mineral. 16:211-212 (1992).
5. Peroutka, S. J. Handbook of Receptors and Channels. CRC Press, Boca Raton, FL (1994).
6. Sexton, P. M., S. Houssami, J. M. Hilton, L. M. O'Keeffe, R. J. Center, M. T. Gillespie, P. Darcy, and D. M. Findlay. Identification of brain isoforms of the rat calcitonin receptor. Mol. Endocrinol. 7:815-821 (1993).
7. Moore, E. E., R. E. Keustner, S. D. Stroop, F. J. Grant, S. L. Matthewes, C. L. Brady, P. M. Sexton, and D. M. Findlay. Functionally different isoforms of the human calcitonin receptor result from alternative splicing of the gene transcript. Mol. Endocrinol. 9:959-968 (1995).
8. Yamin, M., A. H. Gorn, M. R. Flannery, N. A. Jenkins, D. J. Gilbert, N. G. Copeland, D. R. Tapp, S. M. Krane, and S. R. Goldring. Cloning and characterisation of a mouse brain calcitonin receptor complementary deoxyribonucleotide acid and mapping of the calcitonin receptor gene. Endocrinology 135:2635-2643 (1994).
9. Horne, W. C., J.-F. Shyu, M. Chakraborty, and R. Baron. Signal transduction by calcitonin: multiple ligands, receptors, and signalling pathways. Trends Endocrinol. Metab. 5:395-401 (1994).
10. Chakraborty, M., D. Chatterjee, S. Kellokumpu, H. Rasmussen, and R. Baron, Cell cycle-dependent coupling of the calcitonin receptor to different G proteins. Science (Washington D. C.) 251:1078-1082 (1991).
11. Houssami, S., D. M. Findlay, C. L. Brady, D. E. Myers, T. J. Martin, and P. M. Sexton. Isoforms of the rat calcitonin receptor: consequences for ligand binding and signal transduction. Endocrinology 135:183-190 (1994).
12. 2-adrenergic receptor: extending the ternary complex model. J. Biol. Chem. 268:4625-4636 (1993).
13. Milligan, G., R. A. Bond, and M. Lee. Inverse agonism: pharmacological curiosity or potential therapeutic strategy. Trends. Pharmacol. Sci. 16: 10-13 (1995).
14. Rao, V. R., G. B. Cohen, and D. D. Oprian. Rhodopsin mutation G90D and a molecular mechanism for congenital night blindness. Nature (Lond.). 367:639-642 (1994).
15. 2-adrenoceptor. Nature (Lond.). 374:272-276 (1995).
16. Shenker, A., L. Laue, S. Kosugi, J. J. Merendino, Jr., T Minegishi, and G. B. Cutler, Jr. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature (Lond.). 365: 652-654 (1993).
17. Parma, J., L. Duprez, J. Van Sande, P. Cochaux, C. Gervy, J. Mockel, J. Dumont, and G. Vassart. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature (Lond.). 365:649-651 (1993).
18. Findlay, M,. M. deLuise, V. P. Michelangeli, M. Ellison, and T. J. Martin. Properties of a calcitonin receptor and adenylate cyclase in a human cancer cell line (BEN cells). Cancer Res. 40:1311-1317 (1980).
19. Munson, P. J., and D. Rodbard. LIGAND: a versatile computerized approach for characterisation of ligand-binding systems. Anal. Biochem. 107:220-239 (1980).
20. 2-adrenoceptor. Mol. Pharmacol. 48:316-325 (1995).
21. Seeman, P, H.-C. Guan, and H. H. M. Van Tol. Dopamine D4 receptors elevated in schizophrenia. Nature (Lond.) 365:441-445 (1993).
22. Kosugi, S., F. Okajima, T. Ban, A. Hidaka, A. Shenker, and L. D. Kohn. Substitutions of different regions of the third cytoplasmic loop of the thyrotropin (TSH) receptor have selective effects on constitutive, TSH-, and TSH receptor autoantibody-stimulated phosphoinositide and 3′,5′-cyclic adenosine monophosphate signal generation. Mol. Endocrinol. 7:1009-1020 (1993).
23. 2-adrenergic receptor is constitutively desensitised and phosphorylated. Proc. Natl. Acad. Sci. USA 91:2699-2702 (1994).
24. 2-adrenergic receptor. J. Biol. Chem. 22:16483-16487 (1993).
25. Boone, C., N. G. Davis, and G. F. Sprague, Jr. Mutations that alter the third cytoplasmic loop of the a-factor receptor lead to a constitutive and hypersensitive phenotype. Proc. Natl. Acad. Sci. USA 90:9921-9925 (1993).
26. Robbins, L. S., J. H. Nadeau, K. R. Johnson, M. A. Kelly, L. Roselli-Rehfuss, E. Baack, K. G. Mountjoy, and R. D. Cone. Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function. Cell, 72:827-834 (1993).
27. Lefkowitz, R. J. Turned on to ill effect. Nature (Lond.) 365:603-604 (1993).
28. Feyen, J. H. M., F. Cardinaux, R. Gamse, C. Bruns, M. Azria, and U. Trechsel. N-terminal truncation of salmon calcitonin leads to calcitonin antagonists. Biochem. Biophys. Res. Commun. 187:8-13 (1992).
29. Houssami, S., D. M. Findlay, C. L. Brady, T. J. Martin, R. M. Epand, E. E. Moore, E. Murayama, T. Tamura, R. C. Orlowski, and P. M. Sexton. Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation. Mol. Pharmacol. 47:798-809 (1995).
30. 2-adrenergic receptor. Mol. Pharmacol. 45:390-394 (1993).
31. Nygaard, S. C., R. E. Kuestner, E. E. Moore, and S. D. Stroop. Phosphorylation of the calcitonin receptor localized at the C-terminus. J. Bone Miner. Res. 10 (Suppl. 1):5141 (1995).
32. Allen, L. F., R. J. Lefkowitz, M. G. Caron, and S. Cotecchia. G-protein-coupled receptor genes as protooncogenes: constitutively activating mutation of the α1B-adrenergic receptor enhances mitogenesis and tumorigenicity. Proc. Natl. Acad. Sci. USA 88:11354-11358 (1991).
33. Cook, S. J., and F. McCormick. Inhibition by cAMP of Ras-dependent activation of Raf. Science (Washington D. C.) 262:1069-1072 (1993).
34. Jwu, J., P. Dent, T. Jelinek, A. Wolfman, M. J. Weber, and T. W. Sturgill. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′,5′-monophosphate. Science (Washington D. C.) 262:1065-1069 (1993).
35. Aiyar, N., E. Baker, J. Martin, A. Patel, J. M. Stadel, R. N. Willette, and F. C. Barone. Differential calcitonin gene-related peptide (CGRP) and amylin binding sites in nucleus accumbens and lung: potential models for studying CGRP/amylin receptor subtypes. J. Neurochem. 65:1131-1138 (1995).
36. Sexton, P. M., S. Houssami, C. L. Brady, D. E. Myers, and D. M. Findlay. Amylin is an agonist of the renal porcine calcitonin receptor. Endocrinology. 143:2103-2107 (1994).
37. Chiba, T., A. Yamaguchi, T. Yamatani, A. Nakamura, T. Morishita, T. Inui, M. Fukase, T. Noda, and T. Fujita. Calcitonin gene-related peptide receptor antagonist human CGRP-(8-37). Am. J. Physiol. 256:E331-E335 (1989).
38. Kenakin, T. Pharmacological Analysis of Drug-Receptor Interaction. Raven Press, New York (1993).
39. Meadows, R. P., E. P. Nikonowicz, C. R. Jones, J. W. Bastian, and D. G. Gorenstein. Two-dimensional NMR and structure determination of salmon calcitonin in methanol. Biochemistry 30:1247-1254 (1991).
40. Chidiac, P., T. E. Herbert, M. Valiquette, M. Dennis, and M. Bouvier. Inverse agonist activity of β-adrenergic antagonists. Mol. Pharmacol. 45: 490-499 (1994).